

SAFETY DATA SHEETS

This SDS packet was issued with item:

078912032

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

070393124 070393132

SAFETY DATA SHEET

Product Name: Ketamine Hydrochloride Injection

1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

Manufacturer Name And Address	Hospira, Inc. 275 North Field Drive Lake Forest, Illinois 60045 USA
Emergency Telephone	CHEMTREC: North America: 800-424-9300; International 1-703-527-3887; Australia - 61-290372994; UK - 44-870-8200418
Hospira, Inc., Non-Emergency	224 212-2000
Product Name	Ketamine Hydrochloride Injection
Synonyms	(±)-2-(<i>o</i> -Chlorophenyl)-2-(methylamino) cyclohexanone hydrochloride

2. HAZARD(S) IDENTIFICATION

Emergency Overview	Ketamine Hydrochloride Injection is a solution containing ketamine hydrochloride, a rapid-acting non-barbiturate anesthetic indicated as the sole anesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation. Ketamine is a general anesthetic that is a Schedule III controlled substance. In the workplace, this material should be considered potentially irritating to the eyes and respiratory tract. Based on clinical use, possible target organs include the respiratory system, cardiovascular system, and nervous system.
---------------------------	---

U.S. OSHA GHS Classification

Physical Hazards	Hazard Class	Hazard Category
	Not Classified	Not Classified

Health Hazards	Hazard Class	Hazard Category
	Eye Damage / Irritation	2A
	Skin Irritation	2
	STOT – RE	2

Label Element(s)

Pictogram



Signal Word

Warning

Hazard Statement(s)

Causes serious eye irritation
Causes skin irritation
May cause damage to organs through prolonged or repeated exposure

Precautionary Statement(s)

Prevention

Do not breathe vapor or spray
Wear eye protection/face protection
Wear protective gloves
Wash hands thoroughly after handling

Response

Get medical attention if you feel unwell.

IF ON SKIN: Wash with plenty of water. If skin irritation occurs: Get medical advice/attention. Take off contaminated clothing and wash it before reuse.

IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists, get medical attention.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Active Ingredient Name Ketamine Hydrochloride
Chemical Formula C₁₃H₁₆ClNO•HCl

Component	Approximate Percent by Weight	CAS Number	RTECS Number
Ketamine Hydrochloride	≤ 10	1867-66-9	GW1400000

Non-hazardous ingredients include Water for Injection. Hazardous ingredients present at less than 1% include benzethonium chloride which is added as a preservative.

4. FIRST AID MEASURES

Eye Contact	Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Skin Contact	Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Inhalation	Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Ingestion	Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

5. FIRE FIGHTING MEASURES

Flammability	None anticipated for this aqueous product.
Fire & Explosion Hazard	None anticipated for this aqueous product.
Extinguishing Media	As with any fire, use extinguishing media appropriate for primary cause of fire such as carbon dioxide, dry chemical extinguishing powder or foam.
Special Fire Fighting Procedures	No special provisions required beyond normal firefighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Spill Cleanup and Disposal	Isolate area around spill. Put on suitable protective clothing and equipment as specified by site spill control procedures. Absorb the liquid with suitable material and clean affected area with soap and water. Dispose of spill materials according to the applicable federal, state, or local regulations.
-----------------------------------	--

7. HANDLING AND STORAGE

Handling	No special handling required for hazard control under conditions of normal product use. Ketamine is a general anesthetic that is a Schedule III controlled substance. Additional training may be required for proper handling of controlled substances.
Storage	No special storage required for hazard control. For product protection, follow storage recommendations noted on the product case label, the primary container label, or the product insert.
Special Precautions	No special precautions required for hazard control.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Exposure Guidelines

Component	Exposure Limits			
	OSHA-PEL	ACGIH-TLV	AIHA WEEL	Hospira EEL
Ketamine Hydrochloride	8-hr TWA: Not Established	8-hr TWA: Not Established	8-hr TWA: Not Established	8-hr TWA: Not Established

Notes: OSHA PEL: US Occupational Safety and Health Administration – Permissible Exposure Limit
 ACGIH TLV: American Conference of Governmental Industrial Hygienists – Threshold Limit Value.
 AIHA WEEL: Workplace Environmental Exposure Level
 EEL: Employee Exposure Limit.
 TWA: 8-hour Time Weighted Average.

Respiratory Protection

Respiratory protection is normally not needed during intended product use. However, if the generation of aerosols is likely, and engineering controls are not considered adequate to control potential airborne exposures, the use of an approved air-purifying respirator with a HEPA cartridge (N95 or equivalent) is recommended under conditions where airborne aerosol concentrations are not expected to be excessive. For uncontrolled release events, or if exposure levels are not known, provide respirators that offer a high protection factor such as a powered air purifying respirator or supplied air. A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements must be followed whenever workplace conditions require respirator use. Personnel who wear respirators should be fit tested and approved for respirator use as required.

Skin Protection

If skin contact with the product formulation is likely, the use of latex or nitrile gloves is recommended.

Eye Protection

Eye protection is normally not required during intended product use. However, if eye contact is likely to occur, the use of chemical safety goggles (as a minimum) is recommended.

Engineering Controls

Engineering controls are normally not needed during the normal use of this product.

9. PHYSICAL/CHEMICAL PROPERTIES

Appearance/Physical State	Color of solution may vary from colorless to very slightly yellowish and may darken upon prolonged exposure to light.
Odor	NA
Odor Threshold	NA
pH	3.5 to 5.5
Melting point/Freezing Point	NA
Initial Boiling Point/Boiling Point Range	NA
Flash Point	NA
Evaporation Rate	NA
Flammability (solid, gas)	NA
Upper/Lower Flammability or Explosive Limits	NA
Vapor Pressure	NA
Vapor Density (Air =1)	NA
Relative Density	NA
Solubility	NA
Partition Coefficient: n-octanol/water	NA
Auto-ignition Temperature	NA
Decomposition Temperature	NA
Viscosity	NA

10. STABILITY AND REACTIVITY

Reactivity	Not determined.
Chemical Stability	Stable under standard use and storage conditions.
Hazardous Reactions	Not determined
Conditions to Avoid	Not determined
Incompatibilities	Not determined
Hazardous Decomposition Products	Not determined. During thermal decomposition, it may be possible to generate irritating vapors and/or toxic fumes of carbon oxides (COx), nitrogen oxides (NOx), and hydrogen chloride.
Hazardous Polymerization	Not anticipated to occur with this product.

11. TOXICOLOGICAL INFORMATION

Acute Toxicity - Not determined for the product formulation. Information for the active ingredient is as follows:

Ingredient(s)	Percent	Test Type	Route of Administration	Value	Units	Species
Ketamine Hydrochloride	100	LD50	Oral	447 617	mg/kg mg/kg	Rat Mouse
Ketamine Hydrochloride	100	LD50	Intravenous	58.9 55.9	mg/kg mg/kg	Rat Mouse

LD 50: Dosage that produces 50% mortality.

Occupational Exposure Potential	Information on the absorption of this product via inhalation or skin contact is not available. Avoid liquid aerosol generation and skin contact.
Signs and Symptoms	None anticipated from normal handling of this product. As a drug of abuse, reports suggest that ketamine produces a variety of symptoms including anxiety, dysphoria, disorientation, insomnia, flashbacks, hallucinations, and psychotic episodes. Ketamine dependence and tolerance are possible following prolonged administration. In clinical use, blood pressure and pulse rate may be elevated following administration of ketamine alone. However, hypotension and bradycardia have been observed. Arrhythmia has also occurred. Although respiration is frequently stimulated, severe depression of respiration or apnea may occur following rapid intravenous administration of high doses of ketamine. Laryngospasms and other forms of airway obstruction have occurred during ketamine anesthesia. Diplopia and nystagmus have also been noted, as well as a slight elevation in intraocular pressure. In some patients, enhanced skeletal muscle tone may be manifested by tonic and clonic movements sometimes resembling seizures. Anorexia, nausea and vomiting have also been observed.
Aspiration Hazard	None anticipated from normal handling of this product.
Dermal Irritation/ Corrosion	None anticipated from normal handling of this product.
Ocular Irritation/ Corrosion	None anticipated from normal handling of this product. However, inadvertent contact of this product with eyes may produce irritation with redness and tearing.
Dermal or Respiratory Sensitization	None anticipated from normal handling of this product.
Reproductive Effects	None anticipated from normal handling of this product. Male and female rats given five times the average human intravenous dose of ketamine for three consecutive days about one week before mating had a reproductive performance equivalent to that of controls. When given to pregnant rats and rabbits intramuscularly at twice the average human intramuscular dose during the respective periods of organogenesis, the litter characteristics were equivalent to those of controls.

11. TOXICOLOGICAL INFORMATION: continued

Reproductive Effects: continued	A small group of rabbits was given a single large dose (six times the average human dose) of ketamine on Day 6 of pregnancy. The outcome of pregnancy was equivalent in control and treated groups. To determine the effect of ketamine on the perinatal and postnatal period, pregnant rats were given twice the average human intramuscular dose during Days 18 to 21 of pregnancy. Litter characteristics at birth and through the weaning period were equivalent to those of the control animals. There was a slight increase in incidence of delayed parturition by one day in treated dams of this group. Three groups each of mated beagle females were given 2.5 times the average human intramuscular dose twice weekly for the three weeks of the first, second, and third trimesters of pregnancy, respectively, without the development of adverse effects in the pups.		
Mutagenicity	Ketamine hydrochloride was negative in the Ames test for mutagenicity.		
Carcinogenicity	The carcinogenic potential of this product has not been determined.		
Carcinogen Lists	IARC: Not listed	NTP: Not listed	OSHA: Not listed
Specific Target Organ Toxicity – Single Exposure	NA		
Specific Target Organ Toxicity – Repeat Exposure	Based on clinical use, possible target organs include the respiratory system, cardiovascular system, and nervous system.		

12. ECOLOGICAL INFORMATION

Aquatic Toxicity	Not determined for product.
Persistence/Biodegradability	Not determined for product.
Bioaccumulation	Not determined for product.
Mobility in Soil	Not determined for product.

Notes:

13. DISPOSAL CONSIDERATIONS

Waste Disposal	All waste materials must be properly characterized. Further, disposal should be performed in accordance with the federal, state or local regulatory requirements.
Container Handling and Disposal	Dispose of container and unused contents in accordance with federal, state and local regulations.

14. TRANSPORTATION INFORMATION

ADR/ADG/ DOT STATUS Not regulated
 Proper Shipping Name NA
 Hazard Class NA
 UN Number NA
 Packing Group NA
 Reportable Quantity NA

ICAO/IATA STATUS Not regulated
 Proper Shipping Name NA
 Hazard Class NA
 UN Number NA
 Packing Group NA
 Reportable Quantity NA

IMDG STATUS Not regulated
 Proper Shipping Name NA
 Hazard Class NA
 UN Number NA
 Packing Group NA
 Reportable Quantity NA

Notes: DOT - US Department of Transportation Regulations

15. REGULATORY INFORMATION

US TSCA Status Exempt
 US CERCLA Status Not listed
 US SARA 302 Status Not listed
 US SARA 313 Status Not listed
 US RCRA Status Not listed
 US PROP 65 (Calif.) Not listed

Notes: TSCA, Toxic Substance Control Act; CERCLA, US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act; SARA, Superfund Amendments and Reauthorization Act; RCRA, US EPA, Resource Conservation and Recovery Act; Prop 65, California Proposition 65

GHS/CLP Classification*

*In the EU, classification under GHS/CLP does not apply to certain substances and mixtures, such as medicinal products as defined in Directive 2001/83/EC, which are in the finished state, intended for the final user.

Hazard Class	Hazard Category	Pictogram	Signal Word	Hazard Statement
NA	NA	NA	NA	NA
Prevention	Do not breathe vapor or spray Wear eye protection/face protection Wear protective gloves Wash hands thoroughly after handling			
Response	Get medical attention if you feel unwell. IF ON SKIN: Wash with plenty of water. If skin irritation occurs: Get medical advice/attention. Take off contaminated clothing and wash it before reuse. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists, get medical attention.			

15. REGULATORY INFORMATION: continued

<u>EU Classification*</u>	*Medicinal products are exempt from the requirements of the EU Dangerous Preparations Directive.
Classification(s)	NA
Symbol	NA
Indication of Danger	NA
Risk Phrases	NA
Safety Phrases	S23: Do not breathe vapor/spray S24: Avoid contact with the skin S25: Avoid contact with eyes S37/39 Wear suitable gloves and eye/face protection.

16. OTHER INFORMATION

Notes:

ACGIH TLV	American Conference of Governmental Industrial Hygienists – Threshold Limit Value
CAS	Chemical Abstracts Service Number
CERCLA	US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act
DOT	US Department of Transportation Regulations
EEL	Employee Exposure Limit
IATA	International Air Transport Association
LD ₅₀	Dosage producing 50% mortality
NA	Not applicable/Not available
NE	Not established
NIOSH	National Institute for Occupational Safety and Health
OSHA PEL	US Occupational Safety and Health Administration – Permissible Exposure Limit
Prop 65	California Proposition 65
RCRA	US EPA, Resource Conservation and Recovery Act
RTECS	Registry of Toxic Effects of Chemical Substances
SARA	Superfund Amendments and Reauthorization Act
STEL	15-minute Short Term Exposure Limit
STOT - SE	Specific Target Organ Toxicity – Single Exposure
STOT - RE	Specific Target Organ Toxicity – Repeated Exposure
TSCA	Toxic Substance Control Act
TWA	8-hour Time Weighted Average

MSDS Coordinator: Hospira GEHS
Date Prepared: October 18, 2012
Date(s) Revised: June 02, 2014

Disclaimer:

The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.